HighTide Therapeutics places big IPO bet on “affluenza” drug
The company is pouring almost all its R&D budget into producing a metabolic drug to treat several conditions including diabetes Key Takeaways: With no products yet on the market, HighTide…
FAST NEWS: MicroPort MedBot Revenue Soars in First Full Year of Product Sales
The latest: Surgical robot maker Shanghai MicroPort MedBot (Group) Co. Ltd. (2522.HK) said on Wednesday its revenue jumped by more than 850% last year, while it recorded a net loss…
FAST NEWS: CStone Revenue Doubles, Helping Company Pare Losses
The latest: CStone Pharmaceuticals (2616.HK) announced on Thursday it expects to report its revenue doubled to 475 million yuan ($70 million) or more last year, while its net loss narrowed…
FAST NEWS: InnoCare Pharma Sees Losses Shrinking, But Stock Still Slumps
The latest: Drug maker InnoCare Pharma Ltd. (9969.HK) announced Wednesday evening that it expects to report a net loss of up to 100 million yuan ($15.7 million) for all 2021,…
RELATED ARTICLES
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US -
Akeso marks profit milestone with swift rights issue
9926.HK
-
WuXi Biologics hatches new baby with ADC drug unit IPO
2269.HK
-
Drug maker Junshi seeks Swiss cure for cash woes
1877.HK 688150.SHG
-
Kintor shares plunge after hair-loss drug flops in clinical trials
9939.HK
-
RemeGen hopes for pain relief from expanded drug uses
9995.HK 688331.SHG
-
Everest reaches new heights on growing drug sales
1952.HK
